BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

rVWF: Phase I data

A single-blind, dose-escalating, crossover Phase I trial in 32 patients with type 3 or severe type 1 vWD showed that 2-50 IU/kg rVWF was well tolerated, with no thrombotic or serious adverse...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >